Edwards Lifesciences Corp - Company Profile
Powered by 
All the sales intelligence you need on Edwards Lifesciences Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Edwards Lifesciences Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Edwards Lifesciences Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Edwards Lifesciences Corp (Edwards Lifesciences) is a medical technology company. It develops, manufactures, and markets devices for structural heart disease, critical care and surgical monitoring. The company’s products include surgical valve repair devices, surgical valve replacement, transcatheter heart valves, aortic replacement valves, mitral annuloplasty rings and tricuspid annuloplasty rings. The company's products are used by healthcare professionals to treat patients with various heart valve disorders. Edwards Lifesciences distributes its products through direct sales forces and independent distributors. The company operates manufacturing facilities in the US, Singapore, Costa Rica, and Ireland. Edwards Lifesciences is headquartered in Irvine, California, the US.
Headquarters
United States of America
Address
One Edwards Way, Irvine, California, 92614
Website
www.edwards.com
Telephone
1 949 2502500
No of Employees
16,000
Industry
Medical Equipment
Ticker Symbol & Exchange
EW (NYSE)
Revenue (2024)
$6.1B
11.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-74.3%
(2024 vs 2023)
Market Cap*
$53.0B
Net Profit Margin (2024)
XYZ
-77.0%
(2024 vs 2023)
* As of and is in US$
Edwards Lifesciences Corp premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Surgical Valve Repair: | Cribier-Edwards |
| Mitral Valve Repair | Edwards |
| Tricuspid Valve Repair | Edwards Sapien |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In December, the company received approval from the U.S. Food and Drug Administration for SAPIEN M3 mitral valve replacement system, a transcatheter therapy utilizing a transseptal approach to treat mitral regurgitation. |
| 2025 | Acquisitions/Mergers/Takeovers | In September, the company acquired the remaining 48% stake in Victorious Medical Technologies. |
| 2025 | Regulatory Approval | In May, the company received approval from the US FDA for its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients. |
Competitor Comparison
| Key Parameters | Edwards Lifesciences Corp | Abbott Laboratories | Medtronic Plc | Boston Scientific Corp | ICU Medical Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Ireland | United States of America | United States of America |
| City | Irvine | Abbott | Dublin | Marlborough | San Clemente |
| State/Province | California | Illinois | - | Massachusetts | California |
| No. of Employees | 16,000 | 115,000 | 95,000 | 59,000 | 13,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Bernard J. Zovighian | Director; Chief Executive Officer | Executive Board | 2023 | 58 |
| Doretta Mistras | Corporate Vice President; Chief Financial Officer | Senior Management | 2026 | - |
| Snehashish Sarkar | Senior Vice President; Chief Information & Digital Officer | Senior Management | 2025 | - |
| Todd J. Brinton, M.D. | Chief Scientific OfficerSenior Management | Senior Management | 2019 | - |
| Amit Agarwal | Senior Vice President - Transcatheter Edge-to-Edge Repair Therapies | Senior Management | 2026 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer